|

Bulevirtide Clinical Trials

7 actively recruiting trials

Also known as: BJT-778, Hepcludex

Pipeline

Phase 3: 1Phase 2/3: 1

Top Sponsors

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico3
Vir Biotechnology, Inc.1
Research Center of Periodontal-Systemic Interactions1
Mirum Pharmaceuticals, Inc.1
Karolinska University Hospital1

Indications

Liver Disease7
Hepatitis D4
Chronic Hepatitis D2
Viral Hepatitis1
Periodontitis1

Other7 trials

A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide

Phase 3

Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis

Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD)

Immunological and Virological Characterization of Patients With Chronic HBV-HDV Infection: Outcomes and Response to Bulevirtide Treatment

Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D

Phase 2b/3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide

Phase 2/3

Study to Evaluate Efficacy, Safety and Biomarkers of Bulevirtide Treatment in Chronic Hepatitis D Patients

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.